August 10, 2017

US Bioservices is now dispensing MAVYRET

The U.S. Food and Drug Administration has approved MAVYRET (glecaprevir and pibrentasvir) for the treatment of patients with chronic HCV genotype 1-6 infection without cirrhosis and with compensated cirrhosis. It is also indicated for adult patients with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor, but not both.